Healthcare

Jaguar Health Reports Crofelemer Use in Infant With GUCY2C-Related Intestinal Failure

Jaguar Health says its family company Napo Pharmaceuticals has provided liquid oral crofelemer to an infant with GUCY2C-related intestinal failure, with reported reductions in parenteral support needs.

Published:
Reading Time
3 min

Jaguar Health, Inc. (NASDAQ:JAGX) said its family company Napo Pharmaceuticals has continued providing crofelemer powder for oral solution to an infant with intestinal failure caused by a GUCY2C mutation resulting in congenital sodium diarrhea. The company said treatment had been provided for several weeks and was associated with an approximately 15% reduction in the patient’s daily parenteral support needs within the first several weeks.

#GUCY2C case under expanded access

According to Jaguar, the liquid oral formulation has been well tolerated in the pediatric patient, with no significant clinical or laboratory abnormalities reported. The infant continues to require significant daily parenteral support.

Jaguar described GUCY2C mutation-related congenital sodium diarrhea as the third intestinal failure-related congenital enteropathy being evaluated through expanded access. The other conditions identified by the company are pediatric microvillus inclusion disease (MVID) and short bowel syndrome-related intestinal failure (SBS-IF).

#Parenteral support in intestinal failure

Patients with intestinal failure may be unable to absorb sufficient nutrients, electrolytes and fluids through the digestive system. Jaguar said some patients require lifelong total parenteral nutrition, with or without supplemental intravenous fluids. Together, these treatments make up parenteral support, which may be required for up to seven days per week and up to 20+ hours per day.

The company described parenteral support as supportive and lifesaving, while also stating that it can involve serious, sometimes fatal complications. Jaguar added that children with GUCY2C-related congenital sodium diarrhea face challenges in managing nutritional and electrolyte deficiencies because of the effects on growth and developmental needs.

#Reported results in MVID and SBS-IF

Jaguar said ongoing investigations of liquid oral crofelemer in pediatric intestinal failure have shown reductions in weekly parenteral support requirements, including when those requirements are normalised to body weight. The company reported no significant clinical or laboratory abnormalities in these investigations.

In one pediatric MVID patient, weekly parenteral support requirements normalised to body weight were reduced by up to 48% following >12 months of liquid oral high-dose crofelemer therapy, according to Jaguar.

Jaguar also reported that, in two pediatric SBS-IF patients, weekly parenteral support requirements normalised to body weight were reduced up to 40% following >12 months of liquid oral high-dose crofelemer therapy.

#Planned MVID regulatory filing

Jaguar said it plans to file a New Drug Application for crofelemer in MVID in mid-2027 to seek approval from the U.S. Food and Drug Administration. The company said the proposed application would include data from an ongoing pivotal trial, which has completed enrollment.

Napo is continuing its global development programme for oral crofelemer as adjunctive therapy to parenteral support in pediatric rare intestinal failure diseases, according to Jaguar.

#About crofelemer

Jaguar describes crofelemer as an oral plant-based prescription medicine purified from the red bark sap of the Croton lechleri tree, also known as “dragon’s blood,” in the Amazon Rainforest. The company said Napo has established a harvesting programme under fair trade practices for the medicine.

Jaguar Health is a commercial-stage pharmaceuticals company developing prescription medicines derived from plants from rainforest areas for gastrointestinal distress in people and animals. Its family companies Napo Pharmaceuticals and Napo Therapeutics focus on crofelemer powder for oral solution for rare and orphan gastrointestinal disorders involving intestinal failure, including MVID and SBS.

#Key Takeaways

  • Jaguar Health said Napo Pharmaceuticals has provided liquid oral crofelemer to an infant with GUCY2C-related congenital sodium diarrhea and intestinal failure.
  • The company reported an approximately 15% reduction in the patient’s daily parenteral support needs within the first several weeks.
  • Jaguar said GUCY2C-related congenital sodium diarrhea is the third intestinal failure-related congenital enteropathy being evaluated under expanded access.
  • The company plans to file an NDA for crofelemer in MVID in mid-2027, based on data that will include results from a pivotal trial that has completed enrollment.

Original source: Read original article

Frequently Asked Questions